Retrospective Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jan 28, 2017; 23(4): 676-686
Published online Jan 28, 2017. doi: 10.3748/wjg.v23.i4.676
Table 1 Clinicopathologic characteristics of the patients n (%)
Characteristic (n = 212)Frequency, mean ± SD
Age (yr)62.8 ± 9.5
Male gender125 (59.0)
BMI (kg/m2)22.8 ± 2.9
Diabetes73 (34.4)
ASA
166 (31.1)
292 (43.4)
349 (23.1)
42 (0.9)
Operative time (min)402.2 ± 129.3
Intraoperative bleeding (mL)626.0 ± 482.8
Intraoperative transfusion47 (22.2)
pT stage
T09 (4.2)
T116 (7.5)
T23 (1.4)
T3182 (85.8)
T42 (0.9)
pN stage
N0106 (50.0)
N1106 (50.0)
pTNM staging
I18 (8.5)
II182 (85.8)
III2 (0.9)
IV1 (0.5)
R status
R0187 (88.2)
R123 (10.8)
R22 (0.9)
Cell differentiation
Well24 (11.3)
Moderate152 (71.7)
Poor17 (8.0)
Undifferentiated1 (0.5)
Retrieved lymph nodes17.3 ± 9.9
Vascular resection55 (25.9)
Mutivisceral resection36 (17.5)
Combined resection71 (33.5)
Lymphovascular invasion71 (33.5)
Perineural invasion146 (68.9)
Neoadjuvant CCRT66 (31.3)
Adjuvant treatment154 (72.6)
Complications
Minor112 (52.8)
Major(≥ G3)20 (9.4)
Length of hospital stay (d)21.1 ± 15.0
Recurrence137 (64.6)
Table 2 Clinicopathologic differences between the good pain control group and poor pain control group undergoing distal pancreatectomy n (%)
Pain control group
P value
Good(n = 53)Poor(n = 13)
Age (yr)65.6 ± 8.263.2 ± 11.30.378
Male gender30 (56.6)7 (53.8)0.858
BMI (kg/m2)23.1 ± 2.723.1 ± 2.40.993
Diabetes17 (32.1)3 (23.1)0.739
ASA
116 (30.2)5 (41.7)0.342
222 (41.5)6 (50.0)
315 (28.3)1 (8.3)
Surgical approach
Open35 (66.0)7 (53.8)0.523
MIS18 (34.0%)6 (46.2)
Spleen preservation7 (13.2)2 (15.4)> 0.999
Operation time (min)254.1 ± 95.3304.6 ± 89.00.088
Intraoperative bleeding (mL)364.2 ± 296.0470.38 ± 624.80.373
Intraoperative transfusion5 (9.4)3 (23.1)0.185
Tumor size (cm)0.407
< 330 (56.6)9 (69.2)
≥ 323 (43.4)4 (30.8)
pT stage0.148
T03 (5.7)0 (0)
T13 (5.7)2 (15.4)
T22 (3.8)1 (7.7)
T345 (84.9)9 (69.2)
T40 (0.0)1 (7.7)
pN stage0.851
N027 (50.9)7 (53.8)
N126 (49.1)6 (46.2)
pTNM staging0.429
I5 (9.5)2 (15.4)
II44 (83.0)10 (77.0)
III0 (0.0)1 (7.7)
IV1 (1.9)0 (0.0)
R status0.121
R047 (88.7)11 (84.6)
R16 (11.3 )1 (7.7)
R20 (0.0 )1 (7.7)
Retrieved lymph nodes14.8 ± 11.014.2 ± 6.60.735
Multivisceral resection12 (22.6)2 (15.4)0.718
Combined resection14 (26.4)2 (15.4)0.496
Lymphovascular invasion14 (27.5)4 (33.3)0.729
Perineural invasion34 (66.7)5 (41.7)0.185
Grade0.499
Well3 (6.4)2 (16.7)
Moderate38 (80.9)9 (75.0)
Poor6 (12.8)1 (8.3)
Neoadjuvant CCRT12 (22.6)4 (30.8)0.719
Preoperative CA19-90.154
< 30034 (69.4)12 (92.3)
≥ 30015 (30.6)1 (7.7)
Adjuvant treatment39 (73.6)9 (69.2)0.739
Time to adjuvant treatment (d)53.7 ± 36.863.0 ± 47.00.520
Complications
Minor33 (62.3)7 (53.8)0.578
Major(≥ G3)3 (7.3)2 (28.6)0.148
Use of PCA0.445
IV PCA34 (64.2)10 (76.9)
Epidural PCA17 (32.1)2 (15.4)
None2 (3.8)1 (7.7)
Length of hospital stay (d)17.1 ± 11.027.2 ± 45.90.446
Table 3 Univariate analysis of factors affecting disease-free survival and overall survival after distal pancreatectomy
nDFS
OS
Median survival (mo)P value1Median survival (mo)P value1
Age
< 6530150.216420.150
≥ 65361123
Sex
Female29110.136270.829
Male371833
BMI (kg/m2)
< 2552110.209300.384
≥ 251427
Diabetes
No46130.674270.654
Yes2015
ASA
1/249130.569300.903
3/41615
Surgical approach
Open42140.971300.645
MIS241141
Spleen preservation
Yes9150.931270.619
No571333
Operation time (min)
< 30039170.254410.035
≥ 300271315
Bleeding (mL)
< 50042110.632300.881
≥ 500231533
Intraoperative transfusion
No58150.005330.056
Yes8413
Resection status
R058130.689300.382
R1/R281321
Lymph node status
N0340.011410.020
N132917
Tumor size (cm)
< 339180.028420.023
≥ 327815
pT stage
≤ 2110.293210.949
≥ 3551333
Multivisceral resection
No52150.111330.043
Yes141013
Combined resection
No50150.474330.303
Yes161015
Lymphovascular invasion
No45110.259230.762
Yes181830
Perineural invasion
No24110.947210.621
Yes391527
Neoadjuvant CCRT
Yes16150.351330.433
No501121
Preop CA19-9 (U/mL)
< 30046150.782270.540
≥ 300161342
Adjuvant treatment
Yes48150.094410.017
No1848
Major complications (≥ G3)
No43150.813420.916
Yes5421
Use of PCA
Epidural19130.757270.943
IV441533
Pain control
Good53180.001420.001
Poor13815
Table 4 Univariate and multivariate Cox regression analysis of factors affecting disease-free survival and overall survival after distal pancreatectomy
VariablesDisease-free survival
Overall survival
Univariate analysis
Multivariate analysis
Univariate analysis
Multivariate analysis
Exp (β)95%CIP valueExp (β)95%CIP valueExp (β)95%CIP valueExp (β)95%CIP value
Positive lymph node status2.1831.162-4.1010.0112.2591.150-4.4370.0182.1051.094-4.0530.022.5011.218-5.1340.012
Tumor size (≥ 3 cm)1.9430.999-3.7810.0282.2151.130-4.3410.0212.0301.016-4.0550.0232.6621.282-5.5290.009
No adjuvant treatment1.7420.800-3.7940.0942.4681.196-5.0930.0152.2050.981-4.9550.0174.6492.124-10.172< 0.001
Poor pain control2.9341.158-7.4300.0014.1571.938-8.915< 0.0012.9151.156-7.3500.0014.7412.214-10.153< 0.001
Age (≥ 65 yr)NDND1.6080.844-3.0640.1501.7060.799-3.6400.167
Sex (Male)0.6320.338-1.1810.1360.6140.318-1.1860.146NDND
Operation time (≥ 300 min)NDND1.9490.981-3.8730.0351.8900.923-3.8680.082
Intraoperative transfusion2.7880.903-8.6120.0051.7450.688-4.4250.2412.1590.729-6.3960.0561.9860.750-5.2570.167
Multivisceral resection1.7200.769-3.8490.1111.1660.532-2.5570.7012.0460.837-5.0060.0431.2730.563-2.8760.562